OTC laxatives
This article was originally published in The Tan Sheet
Executive Summary
FDA should deny C.B. Fleet's citizen petition to amend OTC laxative tentative final monograph requesting professional labeling for sodium phosphate oral solution, Braintree Laboratories says in recent comments to the agency. Fleet requested special warnings and directions for two 30 ml to 45 ml doses taken 10 to 12 hours apart (1"The Tan Sheet" Aug. 4, 2003, p. 12). However, Braintree maintains the studies presented by Fleet are flawed in part because they excluded individuals contraindicated to take the drug. "This is precisely the problem, where, due to its OTC status, there exists a perception of safety such that many practitioners are clearly unaware of the contraindication," the comments assert. Adverse events experienced by the study participants should be seriously considered, as those individuals are assumed to be the correct target population for the solution, Braintree adds...
You may also be interested in...
Professional Labeling For OTC Sodium Phosphates Laxatives Requested
C.B. Fleet is asking that the tentative final monograph on OTC laxatives be expanded to include professional labeling for sodium phosphates oral solution
US FDA’s Anti-Misinformation Campaigns Look Safer After Supreme Court Oral Arguments
FDA’s efforts to tackle misinformation may face fewer legal obstacles moving forward, following oral arguments at the Supreme Court on a case that could have broad ramifications for how the government communicates public health information.
The Dog That Didn’t Bark: ODAC Gives Nod To Three Products Despite Negative FDA Reviews
Oncologic Drugs Advisory Committee was swayed by views of its disease area experts in favorably reporting out Geron’s imetelstat for myelodysplastic syndromes and supplemental applications for the CAR-T products Carvykti and Abecma in earlier lines of multiple myeloma.